Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002)

Diagnostic Microbiology and Infectious Disease

Volumn 47, Issue 3, 2003, Pages 515-525

  Sader, Helio S ^a,b   Fritsche, Thomas R ^a   Mutnick, Alan H ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antimicrobial resistance; Cefdinir; H. influenzae; M. catarrhalis; S. pneumoniae

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFDINIR; CEFPROZIL; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; CLINDAMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; PENICILLIN G;

ADOLESCENT; ADULT; AGED; ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BIOLOGICAL MONITORING; CHILD; COMMUNITY; CONTROLLED STUDY; DILUTION; DRUG ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG SCREENING; HAEMOPHILUS INFLUENZAE; HEALTH CENTER; HUMAN; IN VITRO STUDY; INFECTION SENSITIVITY; MORAXELLA CATARRHALIS; NONHUMAN; PATIENT; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 0242285510     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(03)00165-2     Document Type: Article

References (58)

1. Abraham E.P., Newton G.G.F. The structure of cephalosporin C. Biochem J. 79:1961;377-393.
2. Adler M., McDonald P.J., Trostmann U., Keyserling C., Tack T. Cefdinir vs. amoxicillin/clavulanic acid in the treatment of suppurative acute otitis media in children. Pediatr Infect Dis J. 19:2000;S166-S170.
3. Policy statement recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis (RE9960) . Pediatrics. 106:2000;362-366.
4. Baquero F. Evolving resistance patterns of Streptococcus pneumoniae a link with long-acting macrolide consumption? J Chemother. 11:1999;35-43.
5. Block S.L., Hedrick J.A., Kratzer J., Nemeth M.A., Tack R.J. Five-day twice daily cefdinir therapy for acute otitis media microbiologic and clinical efficacy . Pediatr Infect Dis J. 19:2000;S153-S158.
6. Block S.L., Kratzer J., Nemeth M.A., Tack R.J. Five-day cefdinir course vs. ten-day cefprozil course for treatment of acute otitis media. Pediatr Infect Dis J. 19:2000;S147-S152.
7. Block S.L., McCarty J.M., Hedrick J.A., Nemeth M.A., Keyserling C.H., Tack K.J. Comparative safety and efficacy of cefdinir vs. amoxicillin/ clavulanate for the treatment of suppurative acute otitis media in children. Pediatr Infect Dis J. 19:2000;S159-S165.
8. Briggs B.M., Jones R.N., Erwin M.E., Barrett M.S., Johnson D.M. In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393) a novel orally administered cephalosporin . Diagn Microbiol Infect Dis. 14:1991;425-434.
9. Bronzwaer S.L.A.M., Cars O., Buchholz U., Molstad S., Goettsch W., Veldhuijzen I.K., Kool J.L., Sprenger M.J.W., Degener J.E. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis. 8:2002;278-282.
10. Bryskier A. Novelties in the field of anti-infective compounds in 1999. Clin Infect Dis. 31:2000;1423-1466.
11. Buschelman B.J., Jones R.N., Bale M.J. Effects of blood medium supplements on activities of newer cephalosporins tested against enterococci. J Clin Microbiol. 32:1994;565-567.
12. Facilitating influenza and pneumococcal vaccination through standing orders programs. Morbidity and Mortality Weekly Report. 52:2003;68-69.
13. Prevention of pneumococcal disease recommendations of the Advisory Committee on Immunization Practices (ACIP) . Morbidity and Mortality Weekly Report. 46:1997;1-24.
14. Resistance of Streptococcus pneumoniae to fluoroquinolones United States, 1995-1999 . Morbidity and Mortality Weekly Report. 5:2001;800-804.
15. Chen D.K., McGeer A., De Azavedo J.C., Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med. 341:1999;233-239.
16. Cizman M. The use and resistance to antibiotics in the community. Int J Antimicrob Agents. 21:2003;297-307.
17. Cohen M.A., Joannides E.T., Roland G.E., Meservey M.A., Huband M.D., Shapiro M.A., Sesnie J.C., Heifetz C.L. In vitro evaluation of cefdinir (F. K482), a new oral cephalosporin with enhanced antistaphylococcal activity and -lactamase stability. Diagn Microbiol Infect Dis. 18:1994;31-39.
18. Dagan R. Streptococcus pneumoniae in the potential effects of new vaccines on the pattern of antibiotic drug usage in pediatrics. Curr Ther Res. 63:2002;695-706.
19. Doern G.V. Activity of oral β-lactam antimicrobial agents versus respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the era of antibiotic resistance. Otolaryngol Head Neck Surg. 127:(suppl. 6):2002;S17-S23.
20. Fedson D.S., Houck P., Bratzler D. Hospital-based influenza and pneumococcal vaccination Sutton's Law applied to prevention . Infect Control Hospital Epidemiol. 21:2000;692-699.
21. Fireman, B., Black, S. B., Shinefield, H. R., Lee, J., Lewis, E., & Ray, P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 22, 10-16.
22. Gerlach E.H., Jones R.N., Allen S.D., Koontz F.P., Murray P.R., Pfaller M.A., Washington J.A., Erwin M.E. Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC Quality Control Guidelines. Diagn Microbiol Infect Dis. 15:1992;537-543.
23. Guay D. Cefdinir an expanded-spectrum oral cephalosporin . Ann Pharmacother. 34:2000;1469-1477.
24. Guay D. Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin. Pediatr Infect Dis J. 19:2000;S141-S146.
25. Hoban D., Doern G., Fluit A., Roussel-Delvallez M., Jones R.N. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 32:(suppl. 2):2001;S81-S93.
26. Hyde T.B., Gay K., Stephens D.S., Vugia D.J., Pass M., Johnson S., Barrett N.L., Schaffner W., Cieslak P.R., Maupin P.S., Zell E.R., Jorgensen J.H., Facklam R.R., Whitney C.G. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA. 286:2001;1857-1862.
27. Inamoto Y., Chiba T., Kamimura T., Takaya T. FK 482, a new orally active cephalosporin synthesis and biological properties. J Antibiot. XLI:1998;828-830.
28. Johnson, D. M., Sader, H. S., Fritsche, T. R., Biedenbach, D. J., Jones, R. N. (2003). Susceptibility trends of Haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 47, 373-376.
29. Jones R.N. Microbiology of newer fluoroquinolones focus on respiratory pathogens . Diagn Microbiol Infect Dis. 44:2002;213-220.
30. Jones R.N., Pfaller M.A. Bacterial resistance a worldwide problem . Diagn Microbiol Infect Dis. 31:1998;379-388.
31. Jones R.N., Pfaller M.A. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance data from the SENTRY Antimicrobial Surveillance Program . Clin Infect Dis. 31:2000;S16-23.
32. Jones R.N., Biedenbach D.J., Beach M.L. Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2001) report from the SENTRY Antimicrobial Surveillance Program . Diagn Microbiol Infect Dis. 46:2003;77-80.
33. Karlowsky J.A., Thornsberry C., Jones M.E., Evangelista A.T., Critchley I.A., Sahm D.F. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States results from the TRUST Surveillance Program (1998-2002) . Clin Infect Dis. 36:2003;963-970.
34. Klein D.L. Pneumococcal disease and the role of conjugate vaccines. Microb Drug Resist. 5:1999;147-157.
35. Klein J.O., McCracken G.H. Summary role of a new oral cephalosporin, cefdinir, for therapy of infections of infants and children . Pediatr Infect Dis J. 19:2000;S181-S183.
36. Leibovitz E., Satran R., Pigalansky L., Raiz S., Press J., Leiberman A., Dagan R. Can acute otitis media caused by Haemophilus influenzae be distinguished from that caused by Streptococcus pneumoniae? Pediatr Infect Dis J. 22:2003;509-514.
37. Low D.E. The new oral cephalosporins in community-acquired infections. Clin Microbiol Infect. 6:(suppl. 3):2000;64-69.
38. McCormick A.W., Whitney C.G., Farley M.M., Lynfield R., Harrison L.H., Bennett N.M., Schaffner W., Reingold A., Hadler J., Cieslak P., Samore M.H., Lipsitch M. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med. 9:2003;424-430.
39. Mine Y., Kamimura T., Watanabe U., Tawara S., Matsumoto Y., Shibayama F., Kikuchi H., Takaya T., Kuwahara S. In vitro antibacterial activity of FK482 a new orally active cephalosporin . J Antibiot. 41:1988;1873-1889.
40. Methods for dilution antimicrobial tests for bacteria that grows aerobically. Approved standard M7-A6. 2003;NCCLS, Wayne, PA.
41. Performance standards for antimicrobial susceptibility testing. Supplemental tables, M100-S13. 2003;NCCLS, Wayne, PA.
42. st, 2003.
43. Neu H.C., Chin N.X., Labthavikul P. Comparative in vitro activity and β-lactamase stability of FR 17027, a new orally active cephalosporin. Antimicrob Agents Chemother. 26:1984;174-180.
44. Neu H.C., Saha G., Chin N.X. Comparative in vitro activity and β-lactamase stability of FR 17027, a new orally active cephalosporin. Antimicrob Agents Chemother. 33:1989;1795-1800.
45. Package insert. (2001). Omnicef (cefdinir). Chicago IL. [Abbott Laboratories Web site]. February, 2001. Available at http://www.rxabbott.com/ pdf/omnicef.PDF. Accessed on March 31, 2003.
46. Piglansky L., Leibovitz E., Raiz S., Greenberg D., Press J., Leiberman A., Dagan R. Bacteriologic and clinical efficacy of high dose amoxicillin for therapy of acute otitis media in children. Pediatr Infect Dis J. 22:2003;405-412.
47. Pihlajamaki M., Kaijalainen T., Huovinen P., Jalava J. Rapid increase in macrolide resistance among penicillin non-susceptible pneumococci in Finland, 1996-2000. J Antimicrob Chemother. 49:2002;785-792.
48. Pihlajamaki M., Kotilainen P., Kaurila T., Klaukka T., Palva E., Huovinen P. Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. Clin Infect Dis. 33:2001;483-488.
49. Powers J.L., Gooch W.M., Oddo L.P. Comparison of the palatability of the oral suspension of cefdinir vs. amoxicillin/clavulanate potassium, cefprozil and azithromycin in pediatric patients. Pediatr Infect Dis J. 19:2000;S174-S180.
50. Robinson K.A., Baughman W., Rothrock G., Barrett N.L., Pass M., Lexau C., Damaske B., Stefonek K., Barnes B., Patterson J., Zell E.R., Schuchat A., Whitney C.G. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA. 285:2001;1729-1735.
51. Scriver S.R., Willey B.M., Low D.E., Simor A.E. Comparative in vitro activity of cefidinor (CI-983; FK-482) against staphylococci, gram-negative bacilli and respiratory tract pathogens. Eur J Clin Microbiol Infect Dis. 11:1992;646-652.
52. Shlaes D.M., Gerding D.N., John J.F. Jr., Craig W.A., Bornstein D.L., Duncan R.A., Eckman M.R., Farrer W.E., Greene W.H., Lorian V., Levy S., McGowan J.E. Jr., Paul S.M., Ruskin J., Tenover F.C., Watanakunakorn C. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance guidelines for the prevention of antimicrobial resistance in hospitals . Clin Infect Dis. 25:1997;584-599.
53. Sisk J.E., Moskowitz A.J., Whang W., Lin J.D., Fedson D.S., McBean A.M., Plouffe J.F., Cetron M.S., Butler J.C. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA. 278:1997;1333-1339.
54. Thornsberry C., Ogilvie P.T., Holley H.P., Jr., Sahm D.F. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U. S. study. Antimicrob Agents Chemother. 43:1999;2612-2623.
55. Tomasz A., Corso A., Severina E.P., Echaniz-Aviles G., Brandileone M.C., Camou T., Castaneda E., Figueroa O., Rossi A., DiFabio J.L. Molecular epidemiologic characterization of penicillin-resistant Streptococcus pneumoniae invasive pediatric isolates recovered in six Latin American countries an overview . Microb Drug Resist. 4:1998;195-207.
56. Whitney, C. G., Farley, M. M., Hadler, J., Harrison, L. H., Bennett, N. M., Lynfield, R., Reingold, A., Cieslak, P. R., Pilishvili, T., Jackson, D., Facklam, R. R., Jorgensen, J. H., Schuchat, A., for the Active Bacterial Core Surveillance of the Emerging Infections Program Network (200). Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348, 1737-1746.
57. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Lexau C., Reingold A., Lefkowitz L., Cieslak P.R., Cetron M., Zell E.R., Jorgensen J.H., Schuchat A. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 343:2000;1917-1924.
58. Wise R., Andrews J.M., Thornber D. The in vitro activity of cefdinir (FK482), a new oral cephalosporin. J Antimicrob Chemother. 28:1991;239-248.